clinical trial Archives
Jan. 4, 2018—The growing list of patients needing liver transplants continues to outpace the number of available donor organs, but a new preservation and transport device for donor livers could possibly make a big difference.
Oct. 26, 2017—Vanderbilt researcher Tonia Rex, Ph.D., is accustomed to performing studies in her lab with a goal of translating the findings into better diagnoses and treatment tools for the visually impaired.
Oct. 26, 2017—Vanderbilt-Ingram Cancer Center (VICC) has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.
Aug. 31, 2017—Vanderbilt University Medical Center (VUMC) is studying the safety of a possible treatment for diabetic kidney disease that would delay or prevent the need for kidney replacement such as dialysis.
Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
Jul. 20, 2017—Vanderbilt University Medical Center is currently enrolling women to participate in a study looking at the drug Montelukast to treat interstitial cystitis/bladder pain syndrome (IC/BPS).
Jun. 22, 2017—Eighteen-year-old Grace Long had just been accepted at the renowned United States Naval Academy, with plans to become a nuclear engineering officer. Then, she learned she had type 1 diabetes, an immediate disqualifier for military service.
Mar. 30, 2017—Leora Horn, M.D., M.Sc., associate professor of Medicine and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC), has been selected to lead a clinical research trial of combination therapy using two targeted drugs for the treatment of a specific form of lung cancer.
Feb. 9, 2017—Vanderbilt University Medical Center (VUMC) is the first in the state to enroll patients in a clinical trial testing the effectiveness of the newest implantable device used to reduce stroke risk in patients with non-valvular atrial fibrillation (AF), the most common form of arrhythmia.
Oct. 27, 2016—In 2011, doctors at the Vanderbilt Heart and Vascular Institute performed the state’s first transcatheter valve-replacement (TAVR) procedure for high-risk patients suffering from aortic stenosis, the most common valvular heart disease in the United States.
Oct. 20, 2016—Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis.